COVID-19 outpatient treatments
| Treatments | Whoa | When | How | Clinical considerations |
|---|---|---|---|---|
| Molnupiravir | Adults | Start as soon as possible; must begin within 5 days of symptom onset | Taken at home orally | Not recommended in pregnant or lactating women No renal or hepatic adjustment |
| Nirmatrelvir ritonavir | Adults; children ages 12 years and older | Start as soon as possible; must begin within 5 days of symptom onset | Taken at home orally | Renal dosing if estimated glomerular filtration rate is 30–59 mL/min, and not recommended if < 30 mL/min Review drug-drug interactions |
| Remdesivir | Adults and children | Start as soon as possible; must begin within 7 days of symptom onset | Intravenous infusions at a healthcare facility for 3 consecutive days | Consider stopping if patient develops alanine aminotransferase (ALT) elevation ≥ 10 times the upper limit of normal during treatment Discontinue if ALT elevation is accompanied by signs or symptoms of liver inflammation |
↵a Age ≥ 65 years and those with certain underlying medical conditions including: asthma, cancer (hematologic malignancy), cerebrovascular disease, chronic kidney disease (people receiving dialysis), chronic lung diseases (bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, pulmonary hypertension), chronic liver diseases (cirrhosis, nonalcoholic fatty liver disease, alcoholic fatty liver disease, autoimmune hepatitis), cystic fibrosis, diabetes mellitus type 1 and 2, disabilities including Down syndrome, heart disease (heart failure, coronary artery disease, cardiomyopathies), human immunodeficiency virus, mental health conditions (mood disorders, schizophrenia), neurologic conditions (dementia), obesity, physical inactivity, recent or current pregnancy, primary immunodeficiencies, current or former smoking, transplantation, tuberculosis, and use of corticosteroids or immunosuppressive medications.
Information from references 20 and 21.